| Application number | Title of the application | Filing Date | Status |
|---|
| 09/913684 | Antisene modulation of smad2 expression | Feb 28, 2002 | Abandoned |
| 09/913558 | Antisense modulation of smad5 expression | Feb 28, 2002 | Abandoned |
Array
(
[id] => 6750969
[patent_doc_number] => 20030045490
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-03-06
[patent_title] => 'Therapeutic antisense phosphodiesterase inhibitors'
[patent_app_type] => new
[patent_app_number] => 10/076597
[patent_app_country] => US
[patent_app_date] => 2002-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9265
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0045/20030045490.pdf
[firstpage_image] =>[orig_patent_app_number] => 10076597
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/076597 | Therapeutic antisense phosphodiesterase inhibitors | Feb 18, 2002 | Abandoned |
| 09/958236 | Antisense oligonucleotide modulation of stat3 expression | Feb 13, 2002 | Abandoned |
Array
(
[id] => 6721325
[patent_doc_number] => 20030055015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-03-20
[patent_title] => 'Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)'
[patent_app_type] => new
[patent_app_number] => 10/067125
[patent_app_country] => US
[patent_app_date] => 2002-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20941
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0055/20030055015.pdf
[firstpage_image] =>[orig_patent_app_number] => 10067125
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/067125 | Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs) | Feb 3, 2002 | Abandoned |
| 09/958293 | Antisense modulation of microtubule-associated protein 4 expression | Jan 27, 2002 | Abandoned |
Array
(
[id] => 6688882
[patent_doc_number] => 20030032607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-02-13
[patent_title] => 'Antisense oligonucleotide modulation of raf gene expression'
[patent_app_type] => new
[patent_app_number] => 10/057550
[patent_app_country] => US
[patent_app_date] => 2002-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14279
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0032/20030032607.pdf
[firstpage_image] =>[orig_patent_app_number] => 10057550
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/057550 | Antisense oligonucleotide modulation of raf gene expression | Jan 24, 2002 | Issued |
Array
(
[id] => 6755692
[patent_doc_number] => 20030003469
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-01-02
[patent_title] => 'Ribozyme treatment of diseases or conditions related to levels of NF-kappaB'
[patent_app_type] => new
[patent_app_number] => 10/056414
[patent_app_country] => US
[patent_app_date] => 2002-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 10777
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0003/20030003469.pdf
[firstpage_image] =>[orig_patent_app_number] => 10056414
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/056414 | Ribozyme treatment of diseases or conditions related to levels of NF-kappaB | Jan 22, 2002 | Abandoned |
Array
(
[id] => 6847025
[patent_doc_number] => 20030166192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-09-04
[patent_title] => 'Inhibition of interleukin-1-beta secretion by card proteins'
[patent_app_type] => new
[patent_app_number] => 10/050054
[patent_app_country] => US
[patent_app_date] => 2002-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 26612
[patent_no_of_claims] => 112
[patent_no_of_ind_claims] => 30
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0166/20030166192.pdf
[firstpage_image] =>[orig_patent_app_number] => 10050054
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/050054 | Inhibition of interleukin-1-beta secretion by card proteins | Jan 15, 2002 | Abandoned |
| 09/913691 | Antisense modulation of smad1 expression | Jan 10, 2002 | Abandoned |
| 09/913682 | Antisense modulation of g-alpha-12 expression | Jan 9, 2002 | Abandoned |
| 90/006175 | REMEDY FOR DISEASES ASSOCIATED WITH NF-KB | Jan 3, 2002 | Issued |
| 10/030559 | Nucleotide monomer containing six-membered azasugar and antisense oligomers thereof | Jan 2, 2002 | Abandoned |
Array
(
[id] => 1400698
[patent_doc_number] => 06537973
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-03-25
[patent_title] => 'Oligonucleotide inhibition of protein kinase C'
[patent_app_type] => B1
[patent_app_number] => 10/025139
[patent_app_country] => US
[patent_app_date] => 2001-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 18
[patent_no_of_words] => 15048
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/537/06537973.pdf
[firstpage_image] =>[orig_patent_app_number] => 10025139
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/025139 | Oligonucleotide inhibition of protein kinase C | Dec 17, 2001 | Issued |
Array
(
[id] => 6842517
[patent_doc_number] => 20030147864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-08-07
[patent_title] => 'Antisense modulation of CD36L1 expression'
[patent_app_type] => new
[patent_app_number] => 10/024396
[patent_app_country] => US
[patent_app_date] => 2001-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27376
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0147/20030147864.pdf
[firstpage_image] =>[orig_patent_app_number] => 10024396
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/024396 | Antisense modulation of CD36L 1 expression | Dec 17, 2001 | Issued |
Array
(
[id] => 6842516
[patent_doc_number] => 20030147863
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-08-07
[patent_title] => 'Antisense modulation of TFAP2C expression'
[patent_app_type] => new
[patent_app_number] => 10/023782
[patent_app_country] => US
[patent_app_date] => 2001-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26794
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0147/20030147863.pdf
[firstpage_image] =>[orig_patent_app_number] => 10023782
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/023782 | Antisense modulation of TFAP2C expression | Dec 16, 2001 | Abandoned |
Array
(
[id] => 6787713
[patent_doc_number] => 20030138952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-07-24
[patent_title] => 'Antisense modulation of PCTAIRE protein kinase 1 expression'
[patent_app_type] => new
[patent_app_number] => 10/017621
[patent_app_country] => US
[patent_app_date] => 2001-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25710
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0138/20030138952.pdf
[firstpage_image] =>[orig_patent_app_number] => 10017621
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/017621 | Antisense modulation of PCTAIRE protein kinase 1 expression | Dec 6, 2001 | Abandoned |
Array
(
[id] => 6669417
[patent_doc_number] => 20030114401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-06-19
[patent_title] => 'Antisense modulation of Ship-1 expression'
[patent_app_type] => new
[patent_app_number] => 10/003919
[patent_app_country] => US
[patent_app_date] => 2001-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25463
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0114/20030114401.pdf
[firstpage_image] =>[orig_patent_app_number] => 10003919
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/003919 | Antisense modulation of Ship-1 expression | Dec 5, 2001 | Abandoned |
Array
(
[id] => 6682697
[patent_doc_number] => 20030118561
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-06-26
[patent_title] => 'Antisense modulation of phospholipid scramblase 4 expression'
[patent_app_type] => new
[patent_app_number] => 10/012984
[patent_app_country] => US
[patent_app_date] => 2001-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27153
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0118/20030118561.pdf
[firstpage_image] =>[orig_patent_app_number] => 10012984
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/012984 | Antisense modulation of phospholipid scramblase 4 expression | Dec 3, 2001 | Abandoned |
Array
(
[id] => 6756548
[patent_doc_number] => 20030004325
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-01-02
[patent_title] => 'Sugar modified oligonucleotides'
[patent_app_type] => new
[patent_app_number] => 09/996263
[patent_app_country] => US
[patent_app_date] => 2001-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 31426
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0004/20030004325.pdf
[firstpage_image] =>[orig_patent_app_number] => 09996263
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/996263 | Sugar modified oligonucleotides | Nov 27, 2001 | Issued |
